TY - JOUR
T1 - The emerging role of cancer nanotechnology in the panorama of sarcoma
AU - Mercatali, Laura
AU - Vanni, Silvia
AU - Miserocchi, Giacomo
AU - Liverani, Chiara
AU - Spadazzi, Chiara
AU - Cocchi, Claudia
AU - Calabrese, Chiara
AU - Gurrieri, Lorena
AU - Fausti, Valentina
AU - Riva, Nada
AU - Genovese, Damiano
AU - Lucarelli, Enrico
AU - Focarete, Maria Letizia
AU - Ibrahim, Toni
AU - Calabrò, Luana
AU - De Vita, Alessandro
N1 - Funding Information:
This work was supported by the Italian Ministry of Health (GR-2016-47040236) and by Italian Ministry of University and Research (PON- NeON ARS01_00769).
Publisher Copyright:
Copyright © 2022 Mercatali, Vanni, Miserocchi, Liverani, Spadazzi, Cocchi, Calabrese, Gurrieri, Fausti, Riva, Genovese, Lucarelli, Focarete, Ibrahim, Calabrò and De Vita.
PY - 2022/10/17
Y1 - 2022/10/17
N2 - In the field of nanomedicine a multitude of nanovectors have been developed for cancer application. In this regard, a less exploited target is represented by connective tissue. Sarcoma lesions encompass a wide range of rare entities of mesenchymal origin affecting connective tissues. The extraordinary diversity and rarity of these mesenchymal tumors is reflected in their classification, grading and management which are still challenging. Although they include more than 70 histologic subtypes, the first line-treatment for advanced and metastatic sarcoma has remained unchanged in the last fifty years, excluding specific histotypes in which targeted therapy has emerged. The role of chemotherapy has not been completely elucidated and the outcomes are still very limited. At the beginning of the century, nano-sized particles clinically approved for other solid lesions were tested in these neoplasms but the results were anecdotal and the clinical benefit was not substantial. Recently, a new nanosystem formulation NBTXR3 for the treatment of sarcoma has landed in a phase 2-3 trial. The preliminary results are encouraging and could open new avenues for research in nanotechnology. This review provides an update on the recent advancements in the field of nanomedicine for sarcoma. In this regard, preclinical evidence especially focusing on the development of smart materials and drug delivery systems will be summarized. Moreover, the sarcoma patient management exploiting nanotechnology products will be summed up. Finally, an overlook on future perspectives will be provided.
AB - In the field of nanomedicine a multitude of nanovectors have been developed for cancer application. In this regard, a less exploited target is represented by connective tissue. Sarcoma lesions encompass a wide range of rare entities of mesenchymal origin affecting connective tissues. The extraordinary diversity and rarity of these mesenchymal tumors is reflected in their classification, grading and management which are still challenging. Although they include more than 70 histologic subtypes, the first line-treatment for advanced and metastatic sarcoma has remained unchanged in the last fifty years, excluding specific histotypes in which targeted therapy has emerged. The role of chemotherapy has not been completely elucidated and the outcomes are still very limited. At the beginning of the century, nano-sized particles clinically approved for other solid lesions were tested in these neoplasms but the results were anecdotal and the clinical benefit was not substantial. Recently, a new nanosystem formulation NBTXR3 for the treatment of sarcoma has landed in a phase 2-3 trial. The preliminary results are encouraging and could open new avenues for research in nanotechnology. This review provides an update on the recent advancements in the field of nanomedicine for sarcoma. In this regard, preclinical evidence especially focusing on the development of smart materials and drug delivery systems will be summarized. Moreover, the sarcoma patient management exploiting nanotechnology products will be summed up. Finally, an overlook on future perspectives will be provided.
KW - lipid-based nanocarriers
KW - nanotechnology
KW - polymeric nanoparticles
KW - sarcoma
KW - smart materials
UR - http://www.scopus.com/inward/record.url?scp=85140963307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140963307&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2022.953555
DO - 10.3389/fbioe.2022.953555
M3 - Review article
C2 - 36324885
AN - SCOPUS:85140963307
SN - 2296-4185
VL - 10
SP - 953555
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 953555
ER -